

## Press Release Archives

July 26, 2002

### Press reports regarding M/s. Hindustan Motors Ltd.

The press had reports that General Motors India is close to tying up with the Chandrakant Birla-controlled Hindustan Motors for manufacturing engines for its multi-purpose vehicle (MPV) Isuzu Panther.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of Hindustan Motors Limited.

Hindustan Motors Limited has vide its letter inter-alia stated, "The Company has recently been awarded a Letter of Intent by General Motors India Ltd. for supply to them Power Units to be fitted into their new model of utility vehicles to be introduced by them. The arrangement has also been approved by Board of Directors at its meeting held on 24.7.2002 and is subject to necessary approvals from appropriate authorities."

[Top](#)

### Press reports regarding M/s. Glaxo Smithkline Pharmaceuticals Ltd.

The press had reports that there is speculation about Glaxo Smithkline Pharmaceuticals Limited considering a merger with a large international pharma company.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of Glaxo Smithkline Pharmaceuticals Limited.

Glaxo Smithkline Pharmaceuticals Limited has vide its letter inter-alia stated, "We wish to state that this report is the result of the correspondent's own analysis of the global pharmaceutical scene. The report does not pertain to GlaxoSmithKline's operations in India. Most importantly, the report is based on "speculation" about the company considering a merger with a large international pharmaceutical company. It is our policy not to comment on rumours/speculations journalists make. The speculative nature of the report becomes clear from the fact that entire story is based on inputs from pharma analysts and nowhere the company authorities or spokespersons have been quoted."

[Top](#)

### The Exchange has successfully completed its 609<sup>th</sup> Normal Settlement

The Exchange has successfully completed its 609<sup>th</sup> Normal Settlement (Rolling T+3 following SEBI directive) since inception i.e., Settlement Number N - 2002141 on July 26, 2002. The settlement statistics are as follows:

Particulars	Values
	N - 2002141
Total traded quantity (lakhs)	1426.01
Total traded value (Rs. In Crores)	2522.56

Total value of the settlement (Securities) (Rs. In Crores)	330.65
Total value of the settlement (Funds) (Rs. In Crores)	114.42
Shortages for the settlement	0.53%
% of Delivery ( No. of shares delivered / No. of shares traded )	22.35%

[Top](#)